Asthma is a chronic respiratory condition characterized by inflammation, airway obstruction, edema, and mucus production in the lungs. Mesenchymal stem cells (MSCs) have gained attention for their potential therapeutic benefits due to their ability to self-renew and promote tissue repair. This study explores the effects of MSCs in treating asthma in a mouse model. In this experiment, MSCs were administered to asthmatic mice. We then measured key markers of asthma, including the percentage of eosinophils in the blood and bronchoalveolar lavage fluid (BALF), as well as levels of interleukin-4 (IL-4) and Immunoglobulin E (IgE). Additionally, we performed histopathological analysis of lung tissue to assess the degree of inflammation and structural changes. The results showed that MSC treatment significantly reduced eosinophil counts in both the blood and BALF, and lowered levels of IgE and IL-4, which are key markers of allergic inflammation. Furthermore, MSCs helped reduce eosinophilic inflammation, mucus production, and goblet cell hyperplasia in the lungs. Overall, our findings suggest that MSC therapy may offer a promising approach for controlling asthma symptoms and improving lung function, making it a potential treatment option for asthma management.